



WEEKLY WRAP-UP

29TH DECEMBER 2025 - 02ND JANUARY 2026

PROGRESSIVE[®]
Your Progress Our Priority...

www.progressiveshares.com | [f](#) [x](#) [i](#) [@progressiveshar](#) | [🔍](#) Research Analyst

Equities | Derivatives | Commodities | Currency | PMS | Depository | Mutual Funds | NBFC | e-Broking



HIGHLIGHTS OF THE WEEK

29 Dec 2025-02 Jan 2026

DOMESTIC:

- Dr. Reddy's arm receives USFDA complete response letter for AVT03 biosimilar application
- Shakti Pumps wins work order of Rs170.25cr
- NCC bags four new orders worth Rs1,237cr in December
- Hyundai to hike vehicle prices from 01st Jan'26
- NBCC wins orders worth Rs220.31cr from Canara Bank and NVS
- Adani Enterprises completes 39% stake acquisition in Flight Simulation Technique Centre
- Tata Power commissions SJVN's 1GW DCR solar project in Rajasthan
- Devyani International's arm to sell 51% stake in Peanutbutter and Jelly to Heritage Foods
- MapmyIndia adds metro, rail and bus routing to Mappls app for commuters
- Bharat Forge signs its largest small arms contract worth Rs1,662cr with Defence Ministry
- PowerGrid bags 2,000MWh Battery Energy Storage Project in Andhra Pradesh
- IHCL exits Taj GVK after selling 25.52% stake
- Privi Speciality Chemicals block deal: Promoter likely to sell Rs700cr stake
- Radico Khaitan bets on premium products to drive spirits demand
- Arvind Fashions to acquire 31.25% stake of Flipkart in Arvind Youth Brands
- Jindal Steel to double structural steel capacity at Raigarh plant
- L&T wins order for Hyderabad Greenfield Radial Road phase-2 project
- Ola Electric's sales footprint shrinks as stores bet on home inverters
- Lupin signs exclusive India pact with Gan & Lee for fortnightly GLP-1 drug
- Infosys first major IT outsourcer to outline a cut in fresher hiring
- Titan forays into lab-grown diamond jewelry market with beYon brand
- Obesity treatment drugs to be new growth engine for pharma industry: Sun Pharma
- Adani Green Portfolio crosses 17.2GW after commissioning 307MW fresh capacity
- Mahindra bets on AI and skills to drive its 'Tech-First' transformation
- Shriram Finance expects 30-40bps lower NCD rates after rating upgrade
- Govt. claims USD30bn from Reliance, BP for underproduction from gas field
- Remsons Industries bags order worth Rs60cr
- Olectra Greentech begins commercial operations at Hyderabad EV facility

ECONOMY:

- Economy growing at robust pace, banking sector remains sound: RBI report
- RBI flags swelling slippages in unsecured retail lending, particularly among private banks
- India's April-November fiscal deficit at Rs9.76lk-cr, widens on-year to 62.3% of FY26 aim

INDUSTRY:

- Petrochem profitability may remain muted due to oversupply: CareEdge
- Govt. bans sale, use of oral formulations of nimesulide for human use
- Defence Ministry signs Rs4,666cr deals to buy new carbines and torpedoes

HIGHLIGHTS OF THE WEEK

29 Dec 2025-02 Jan 2026

INITIATING TECHNICAL PICK:

Himadri Speciality Chemical Ltd:

CMP-Rs488 | Target Price-Rs636 & Rs784 | Industry-Carbon Black

ICICI Prudential Life Insurance Company Ltd:

CMP-Rs668 | Target Price-Rs787 & Rs906 | Industry-Life Insurance

COVERAGE NEWS:

Indegene Ltd: The company's WoS, Indegene, Inc. USA and Trilogy Writing and Consulting GmbH have signed a share purchase agreement to acquire 100% equity shares in Trilogy Writing & Consulting Inc. for a cash consideration of EUR329,014.

EMS Ltd: The company has entered into a partnership agreement with Neercare India Pvt. Ltd (74% share) and Mr. Gajendra Parihar (75% share) to undertake business related to sewage treatment plant and allied construction materials respectively.

Royal Orchid Hotels Ltd: The company has announced the successful launch of its newest property (36 rooms), Regenta Z at Vadodara.

The Indian Hume Pipe Co. Ltd: The company has executed and registered sale deed for its freehold land situated at Azamabad industrial area, Hyderabad with M/s Ashoka Builders India Pvt. Ltd and has received the entire sales consideration of Rs1739.6mn (an advance of Rs1000mn was already received on 27th Nov'25).

Shilpa Medicare Ltd: Shilpa Pharma Lifesciences Ltd (a material subsidiary) and FTF Pharma Pvt. Ltd (WoS) has received an ex parte ad-interim injunction order from the High Court of Delhi restraining the company from manufacturing, stockpiling, exporting, offering for sale and/or supplying, directly or indirectly, the pharmaceutical drug product containing the compound Ruxolitinib and/or Ruxolitinib salts API along with any other form or compound or formulation which would amount to patent infringement.

Lloyds Engineering Works Ltd: The company has announced strategic merger of Lloyds Infra, Metalfab and Techno Industries into LEWL to create a unified engineering & infrastructure entity with an approx. Rs61.5bn order book (as on H1FY26).

Alkem Laboratories Ltd: (i) The company has acquired 64,02,018 equity shares at issue price of Rs468.60 per equity share aggregating to ~Rs299cr offered by Enzene Biosciences Ltd, a subsidiary of the company, on a rights basis, (ii) The company has received the balance sales consideration worth Rs325mn from Alkem Wellness Ltd (WoS of Alkem) pursuant to the business transfer agreement of trade generics business.

Aurobindo Pharma Ltd: (i) The WoS of the company, CuraTeQ Biologics Private Ltd, has mutually agreed to terminate its agreement with BioFactura Inc, US relating to BFI-751, the proposed ustekinumab biosimilar product. This decision is aligned with CuraTeQ's strategic portfolio prioritisation and is not expected to have a material impact on the company's overall biosimilars strategy, (ii) Auro Pharma Ltd (WoS of Aurobindo) has approved the acquisition of non-oncology prescription formulations business of Khandelwal Laboratories Pvt. Ltd for a cash consideration of Rs3250mn.

Sangam (India) Ltd: The company has entered into an EPC agreement with IB Vogt Solar India Private Limited for setting up a 27MWp solar power plant (for captive power consumption) at Sangarh village in Jaisalmer, Rajasthan.

The Week That Went By:

Nifty50 started the last week of the calendar year on a tepid note, compounding its losses. The Index tested its strong support level of 25,880 during the second trading session and reversed, although the subsequent rally was capped at the 25,970 resistance level. By mid-week, bulls maintained dominance, pushing the Index higher, with support from Mid and Smallcap counters. This trend continued on the last working day; following a steady start, sectoral rotation helped the Index settle the week at a fresh high of 25,628.55, reflecting a total gain of 286.25 points. Barring the FMCG and IT sectors, all others ended in the green, with Metal and PSU Banks performing exceptionally well. Broader markets showed a split performance, with Midcaps advancing by 1.77% and outperforming the Frontline Index, while Smallcaps lagged with gains of 0.77%.

Nifty50=26,328.55

Sensex30=85,762.01

Nifty Midcap 100=61,365.90

Nifty Smallcap100=17,832.05

HIGHLIGHTS OF THE WEEK

29 Dec 2025-02 Jan 2026

NIFTY (WEEKLY)



BANK NIFTY (WEEKLY)



MARKET OUTLOOK

Nifty50 is poised for a potential breakout from a bullish continuation pattern (**Rounding Bottom**). A confirmed breakout could propel the Index towards an upside target of 26,960. With the Index trading in uncharted territory, 26,500 emerges as an untested pivot resistance, while 26,230 is expected to act as immediate support (**L&T-Symmetrical Triangle Breakout, JioFin-Near a Falling Wedge Breakout**). **BankNifty** continues to mirror Nifty50's structure, with 60,500 acting as immediate resistance and 59,800 as key support (**IndusInd Bank-Cup and Handle Pattern Breakout, confirmation awaited**). The **Auto** sector has breached its consolidation phase, resuming its primary uptrend (**Bajaj Auto and TVS Motor-Ascending Triangle Pattern Breakout and Uno Minda-Symmetrical Triangle Breakout**). The **Energy** sector is on the verge of ending its consolidation through a **Symmetrical Triangle** pattern. Several stocks have already witnessed volume-backed breakouts, indicating bullish continuation (**BHEL-Pennant and Pole Breakout, BPCL and HPCL-Rounding Bottom Breakout, CESC, GSPL, NTPC-Falling Wedge Breakout, Coal India-Symmetrical Triangle Breakout, Reliance-Major Consolidation Breakout**). In contrast, the **FMCG** sector has broken down from an eight-month consolidation, signaling a continuation of bearish momentum. For the past couple of weeks, we have been constantly recommending various **Metal counters**, and they performed well, boosting our confidence to remain positive on the same. However, daily charts indicate overbought conditions, suggesting the possibility of a time or price-wise correction to cool off momentum, but the overall uptrend will remain intact (**JSL-Rounding Bottom Breakout, SAIL-Cup and Handle Breakout and Tata Steel-Near Cup and Handle Breakout**). The **PSE** segment has registered a major **Cup and Handle** breakout, with upcoming price action expected to confirm trend sustainability. After a stellar performance, we were anticipating a sideways movement in the **PSU Banking** space, but it broke out from the **Symmetrical Triangle** pattern, indicating a trend continuation. The **Realty** sector has formed consecutive Doji candles, reflecting rejection at lower levels. However, a strong bullish weekly candle is required to confirm any meaningful trend reversal.


HIGHLIGHTS OF THE WEEK

29 Dec 2025-02 Jan 2026

NIFTY 50 COMPONENTS (WEEKLY PERFORMANCE)

Adani Enterprises	2.11%	HDFC Life	0.68%	Reliance	2.12%
Adani Ports	0.20%	Hindalco	6.13%	SBI Life	2.22%
Apollo Hospital	(0.50%)	HUL	2.64%	SBIN	4.05%
Asian Paints	0.91%	ICICI Bank	0.30%	ShriRam Finance	5.17%
Axis Bank	3.25%	Indigo	0.77%	Sun Pharma	0.58%
Bajaj Auto	4.76%	INFY	(0.90%)	Tata Consumer	(0.19%)
Bajaj Finserv	0.97%	ITC	(13.53%)	Tata Steel	8.13%
Bajaj Finance	(0.80%)	JioFin	1.56%	TCS	(0.95%)
BEL	1.26%	JSW Steel	7.66%	Tech Mahindra	(0.02%)
Bharti Airtel	0.12%	Kotak Bank	1.30%	TITAN	1.41%
Cipla	0.40%	LT	2.81%	TMPV	2.86%
Coal India	6.66%	M&M	4.80%	Trent	2.80%
Dr. Reddy's Labs	(0.77%)	Maruti	2.29%	UltraTech	1.21%
Eicher Motors	0.19%	Max Healthcare	(1.11%)	Wipro	1.03%
Eternal	0.80%	Nestle India	0.82%		
Grasim	1.56%	NTPC	8.45%		
HCL Tech	(1.28%)	ONGC	3.14%		
HDFC Bank	0.83%	PowerGrid	2.15%		

SECTORAL PERFORMANCE



HIGHLIGHTS OF THE WEEK

29 Dec 2025-02 Jan 2026

SECTORAL GAINER



SECTORAL LOSER



HIGHLIGHTS OF THE WEEK

29 Dec 2025-02 Jan 2026

DISCLAIMERS AND DISCLOSURES-

Progressive Share Brokers Pvt. Ltd. and its affiliates are a full-service, brokerage and financing group. Progressive Share Brokers Pvt. Ltd. (PSBPL) along with its affiliates are participants in virtually all securities trading markets in India. PSBPL started its operation on the National Stock Exchange (NSE) in 1996. PSBPL is a corporate trading member of Bombay Stock Exchange Limited (BSE), National Stock Exchange of India Limited (NSE) for its stock broking services and is Depository Participant with Central Depository Services Limited (CDSL) and is a member of Association of Mutual Funds of India (AMFI) for distribution of financial products.

PSBPL is SEBI registered Research Analyst under SEBI (Research Analysts) Regulations, 2014 with SEBI Registration No. INH000000859/Research Analyst BSE Enlistment No. 5049. PSBPL hereby declares that it has not defaulted with any stock exchange nor its activities were suspended by any stock exchange with whom it is registered in last five years. PSBPL has not been debarred from doing business by any Stock Exchange / SEBI or any other authorities; nor has its certificate of registration been cancelled by SEBI at any point of time.

PSBPL offers research services to clients as well as prospects. The analyst for this report certifies that all of the views expressed in this report accurately reflect his or her personal views about the subject company or companies and its or their securities, and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report.

Other disclosures by Progressive Share Brokers Pvt. Ltd. (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company (s) covered in this report:-

- PSBPL or its associates financial interest in the subject company: NO
- Research Analyst (s) or his/her relative's financial interest in the subject company: NO
- PSBPL or its associates and Research Analyst or his/her relative's does not have any material conflict of interest in the subject company. The research Analyst or research entity (PSBPL) has not been engaged in market making activity for the subject company.
- PSBPL or its associates actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of publication of Research Report: NO
- Research Analyst or his/her relatives have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of publication of Research Report: NO
- PSBPL or its associates may have received any compensation including for brokerage services from the subject company in the past 12 months. PSBPL or its associates may have received compensation for products or services other than brokerage services from the subject company in the past 12 months. PSBPL or its associates have not received any compensation or other benefits from the Subject Company or third party in connection with the research report. Subject Company may have been client of PSBPL or its associates during twelve months preceding the date of distribution of the research report and PSBPL may have co-managed public offering of securities for the subject company in the past twelve months.
- The research analyst has served as officer, director or employee of the subject company: NO
- Registration granted by SEBI and certification from NISM is in no way guarantee performance of the intermediary or provide any assurance of returns to investors

PSBPL and/or its affiliates may seek investment banking or other business from the company or companies that are the subject of this material. Our sales people, traders, and other professionals may provide oral or written market commentary or trading strategies to our clients that reflect opinions that are contrary to the opinions expressed herein, and our proprietary trading and investing businesses (if any) may make investment decisions that may be inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest including but not limited to those stated herein. Additionally, other important information regarding our relationships with the company or companies that are the subject of this material is provided herein. This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution publication, availability or use would be contrary to law or regulation or which would subject PSBPL or its group companies to any registration or licensing requirement within such jurisdiction. If this document is sent or has reached any individual in such country, especially, USA, the same may be ignored. Unless otherwise stated, this message should not be construed as official confirmation of any transaction. None of the material, nor its content, nor any copy of it, may be altered in any way, transmitted to, copied or distributed to any other party, without the prior express written permission of PSBPL. All trademarks, service marks and logos used in this report are trademarks or registered trademarks of PSBPL or its Group Companies. The information contained herein is not intended for publication or distribution or circulation in any manner whatsoever and any unauthorized reading, dissemination, distribution or copying of this communication is prohibited unless otherwise expressly authorized. Please ensure that you have read "Risk Disclosure Document for Capital Market and Derivatives Segments" as prescribed by Securities and Exchange Board of India before investing in Indian Securities Market. In so far as this report includes current or historic information, it is believed to be reliable, although its accuracy and completeness cannot be guaranteed.

Terms & Conditions:

This report has been prepared by PSBPL and is meant for sole use by the recipient and not for circulation. The report and information contained herein is strictly confidential and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of PSBPL. The report is based on the facts, figures and information that are considered true, correct, reliable and accurate. The information is obtained from publicly available media or other sources believed to be reliable. Such information has not been independently verified and no guaranty, representation of warranty, express or implied, is made as to its accuracy, completeness or correctness. All such information and opinions are subject to change without notice. The report is prepared solely for informational purpose and its at discretion of the clients to buy or sell or subscribe for securities or other financial instruments for the clients. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. PSBPL will not treat recipients as customers by virtue of their receiving this report.

Registered Office Address:

Progressive Share Brokers Pvt. Ltd,
122-124, Laxmi Plaza, Laxmi Indl Estate,
New Link Rd, Andheri West,
Mumbai-400053, Maharashtra
www.progressiveshares.com | Contact No.:022-40777500

Compliance Officer:

Ms. Mamatha Poojari,
Email: compliance@progressiveshares.com,
Contact No.:022-40777500

Grievance Officer:

Email: grievancecell@progressiveshares.com